Enveda Battle Card: $150M Series D Sales Trigger
React to Enveda’s $150M Series D and Phase 1b entry. Pinpoint decision makers. Pitch AI‐metabolomics and automation to crush discovery bottlenecks. Fuel your pipeline.
Published on
Do not index
Do not index
🚀 Battle Card: Enveda
Quick trigger:
👤 Decision Maker in the News
- Mikael Dolsten, Board Member · 🔗 LinkedIn
💡 Why It Matters
- This Enveda sales trigger signals a major capital injection and clinical ramp, accelerating first-in-class small-molecule pipelines across high-value inflammatory diseases. → Source
🎯 Core Pain Point
- Discovery bottlenecks and high costs slowing novel molecule identification
- Lab scale-up challenges to support rapid clinical enrollment
💰 What to Pitch
- Primary: AI & metabolomics platform integration → 4× faster candidate discovery
- Expansion: Automated high-throughput lab systems → 10× lower per-assay costs
🗺️ Quick Context
- HQ: Boulder, CO
- Employees: ≈ 250
- Rev: ≈ $2 M
- Website: enveda.com
🤼 Competitive Intel
*Which other vendors you’ll probably face to win Enveda’s business.*
- Schrödinger — Molecular modeling platform
- Unique edge: Accurate in silico small-molecule predictions
- Evaluated by R&D for design precision
- Dotmatics — Scientific informatics
- Unique edge: Integrated ELN & data management
- Evaluated by Head of Informatics for collaboration workflows
- Benchling — R&D Cloud
- Unique edge: Lab notebook & sample-tracking integration
- Evaluated by CRO & Ops for compliance
- SPT Labtech — Automation & robotics
- Unique edge: High-throughput liquid handling
- Evaluated by Head of Ops for scale
- Thermo Fisher Scientific — Lab instruments & consumables
- Unique edge: End-to-end lab solutions
- Evaluated by Procurement for reliability
✅ Do-Now Checklist
Connect with Mikael Dolsten on LinkedIn (link above)
Send first-touch email + DM using the Copy-My-Prompt block
Schedule CRM follow-ups (Day 3 & Day 10)
Tag opportunity with “Enveda sales trigger” in CRM
Next Step
🧠 Copy My Prompt for Personalized Cold Outreach
────────────────────────────
✏️ YOUR COMPANY
────────────────────────────
OUR_COMPANY = ❑<your company>❑
OFFER_BRIEF = ❑AI-driven metabolomics platform integration❑
PROOF_METRIC = ❑4× faster candidate discovery❑
CTA_STYLE = ❑quick_call❑
TONE = ❑friendly❑
────────────────────────────
📌 TARGET COMPANY
────────────────────────────
NAME = Mikael
COMPANY = Enveda
DEPT = R&D
SIZE = ≈150
BOTTLENECK = Discovery bottlenecks and high costs slowing molecule identification
EVENT = Raised $150M Series D
DETAIL = First patient in Phase 1b for ENV-294
PAIN = Discovery bottlenecks and high costs
SRC = http://cts.businesswire.com/ct/CT?id=ftfLlWd9aZbF2NXfwppam3Bd664=&newsLang=en&newsId=20250904184822&div=41152219
SIM_CO = Schrödinger
WIN_METRIC = 4× faster candidate discovery
NEXT_SIZE = ≈300
EMP_EST = ≈250
REV_EST = ≈$2M
────────────────────────
TASK FOR CHATGPT
────────────────────────
Role: “NewsletterForLeads SDR-Assist”.
Validate any ≈ guesses via SRC.
EMAIL (keep breaks):
Subject: ≈150-person R&D
Mikael—noticed your R&D team is ≈150.
That’s when Discovery bottlenecks and high costs slowing molecule identification slows growth.
We helped Schrödinger fix this with AI-driven metabolomics platform integration.
Result: 4× faster candidate discovery.
Quick call?
PS—next bottleneck hits ≈300.
DM ≤45 words, TONE:
Saw your post about First patient in Phase 1b for ENV-294 — Discovery bottlenecks and high costs.
AI-driven metabolomics platform integration. 4× faster candidate discovery.
Quick chat?